Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1Phase 1/2 1

Status

Completed 5Recruiting 4Terminated 3Not yet recruiting 3Unknown 1Suspended 1Active not recruiting 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 4

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 22Lymphoma, Follicular 14Lymphoma, B-Cell, Marginal Zone 11Lymphoma 11Lymphoma, Mantle-Cell 10Lymphoma, Non-Hodgkin 7Lymphoma, Large B-Cell, Diffuse 6Neoplasms 4Lymphoma, B-Cell 4Recurrence 3Burkitt Lymphoma 3Waldenstrom Macroglobulinemia 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Neoplasm, Residual 1Melanoma 1Mature B-cell Malignancies 1Lymphoproliferative Disorders 1Lymphatic Diseases 1Leukemia, Hairy Cell 1Leukemia, B-Cell 1Leukemia 1Heart Failure 1Extensive Stage Small Cell Lung Cancer 1Dendritic Cell Sarcoma, Interdigitating 1Cytokine Release Syndrome 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1

Interventions

Cyclophosphamide 21fludarabine 14Rituximab 11Immunotherapy, Adoptive 9Specimen Handling 8Vincristine 7Prednisone 7Magnetic Resonance Spectroscopy 7Doxorubicin 7Etoposide 6Biopsy 6glofitamab 5zanubrutinib 4polatuzumab vedotin 4obinutuzumab 4Lenalidomide 4Bendamustine Hydrochloride 4relmacabtagene autoleucel 3loncastuximab tesirine 3fludarabine phosphate 3axicabtagene ciloleucel 3Leukapheresis 3Ifosfamide 3Carboplatin 3tafasitamab 2etoposide phosphate 2X-Rays 2Nivolumab 2Injections 2Disulfides 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Recruiting × Lymphoma, B-Cell × obinutuzumab × Clear all
NCT06634589 2026-06-03

A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies

BeOne Medicines

Phase 1/2 Recruiting
80 enrolled
Lymphoid

Neoplasms, Recurrence, Lymphoma, B-Cell

NCT04970901 2026-03-13

A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)

ADC Therapeutics S.A.

Phase 1 Recruiting
200 enrolled
Lymphoid

Lymphoma, B-Cell

NCT06213311 2026-01-14

A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma

M.D. Anderson Cancer Center

Phase 2 Recruiting
40 enrolled
Lymphoid

Lymphoma, B-Cell

NCT05653271 2025-08-11

ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies

Acepodia Biotech, Inc.

Phase 1 Recruiting
42 enrolled
Lymphoid

Burkitt Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡